Short Interest in Lumos Pharma, Inc. (NASDAQ:LUMO) Rises By 22.7%

Lumos Pharma, Inc. (NASDAQ:LUMO) saw a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 361,500 shares, an increase of 22.7% from the June 30th total of 294,700 shares. Based on an average daily trading volume, of 34,000 shares, the days-to-cover ratio is currently 10.6 days. Currently, 7.0% of the company’s shares are sold short.

Lumos Pharma Trading Up 16.9 %

Shares of LUMO traded up $0.26 during midday trading on Friday, reaching $1.80. 107,193 shares of the company were exchanged, compared to its average volume of 39,660. Lumos Pharma has a 1-year low of $1.37 and a 1-year high of $4.55. The stock has a 50-day moving average price of $2.13 and a 200-day moving average price of $2.61. The company has a market cap of $14.62 million, a price-to-earnings ratio of -0.39 and a beta of 0.72.

Lumos Pharma (NASDAQ:LUMO) last posted its earnings results on Tuesday, May 14th. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.08). The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.51 million. Lumos Pharma had a negative return on equity of 119.87% and a negative net margin of 2,434.69%. During the same period in the previous year, the firm posted ($0.89) earnings per share. Equities research analysts anticipate that Lumos Pharma will post -3.15 earnings per share for the current year.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.